Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Reform Using Part D Model Is Advocacy Priority For PhRMA – Castellani

This article was originally published in The Pink Sheet Daily

Executive Summary

For PhRMA, supporting a move toward privatizing Medicare is a tactic that may help avoid the establishment of new price controls in the system, like the often-discussed mandated drug rebates in Part D.

You may also be interested in...



Romney Advisor Leavitt Champions Part D As Model For Medicare Reform

As the presumptive architect of Republican presidential candidate Mitt Romney’s transition plan, former HHS Secretary Mike Leavitt would be a strong proponent for modeling future Medicare Parts A and B reforms on the Part D program.

CMS Budget Plan: $1 Bil. Increase For Administrative Activities Is New, But Drug Policy Proposals Are Old

CMS budget plan reprises Medicare drug rebates for dual eligibles, eliminating brand/generic patent settlements and other unsuccessful Rx proposals.

PhRMA Hopes To Change Medicare Payment Board Even As It Applauds House-Passed Reform Package

The bill that cleared the House March 21 continues to include creation of an Independent Medicare Advisory Commission with broad powers for implementing cost-cutting measures in Medicare.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS074584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel